Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2623137 | 0.83 | NAMPT (0.50) | KMT2AMEN1NPC1RAB9ABRD4 | |
| SCHEMBL786293 | 0.82 | CCNB2 (0.56) | CCNB2CDK1CCNB1CCNB3KMT2A | |
| SCHEMBL1369225 | 0.77 | XDH (0.41) | BRD4CYP2D6CYP2C19LMNA | |
| SCHEMBL6933552 | 0.76 | ALPL (0.52) | NPC1RAB9AMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL1371823 | 0.76 | XDH (0.40) | BRD4CYP2D6CYP2C19LMNA | |
| SCHEMBL17778780 | 0.76 | XDH (0.42) | NPC1RAB9AMAPTBRD4CYP1A2 | |
| SCHEMBL16147217 | 0.75 | CCNB2 (0.46) | CCNB2CDK1CCNB1CCNB3KMT2A | |
| SCHEMBL1372970 | 0.75 | AURKA (0.45) | BRD4CYP1A2CYP2D6CYP2C9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1370666 | 0.74 | AURKA (0.44) | CYP1A2CYP2D6CYP2C9ALDH1A1LMNA | |
| SCHEMBL23123 | 0.73 | BRD4 (0.64) | NPC1RAB9APOLBBRD4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680262-B2 | Purification of oligonucleotides | GIRINDUS AG (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20130066061-A1 | PURIFICATION OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2013-03-14 | — | — | US | disclosed |
| US-8304532-B2 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-1525212-B1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20110224424-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20100087635-A1 | PURIFICATION OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2010-04-08 | — | — | US | disclosed |
| US-20100069623-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-1846431-A1 | PURIFICATION OF OLIGONUCLEOTIDES | Girindus AG (DE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006079660-A1 | PURIFICATION OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2006-08-03 | — | — | WO | disclosed |
| US-20060089494-A1 | Method for preparing oligonucleotides | GIRINDUS AG (DE) | 2006-04-27 | — | — | US | disclosed |
| EP-1525212-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | Girindus AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004013154-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| EP-1386925-A1 | Method for preparing oligonucleotides | Girindus AG (DE) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069623-A1 | Method for preparing oligonucleotides | RNGTT, NSUN2, RNMT | ROCK1 4744/4885AKR1B1 3587/4885CCNB2 1489/4885 |
| US-20110224424-A1 | Method for preparing oligonucleotides | RNGTT, NSUN2, RNMT | ROCK1 4744/4885AKR1B1 3587/4885CCNB2 1489/4885 |
| US-20060089494-A1 | Method for preparing oligonucleotides | RNGTT, NSUN2, RNMT | ROCK1 4654/4885AKR1B1 682/4885CCNB2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.